Capmatinib

What is Capmatinib?

Capmatinib is a prescription medication used in the treatment of a specific type of lung cancer. It is an oral, small-molecule inhibitor of the MET receptor tyrosine kinase. Marketed under the brand name Tabrecta, it represents a significant advancement in personalized medicine for certain cancer patients. Unlike traditional chemotherapy, Capmatinib is a targeted therapy, meaning it specifically interferes with molecular pathways involved in cancer growth and progression, minimizing harm to healthy cells. Its primary indication is for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific genetic alterations known as MET exon 14 skipping mutations. This medication is taken by mouth, typically twice daily, and requires a physician's prescription and ongoing medical supervision.

How Does it Work?

The mechanism of action of Capmatinib revolves around its ability to selectively inhibit the MET receptor tyrosine kinase. The MET gene provides instructions for making a protein that plays a crucial role in cell growth, survival, and proliferation. In healthy cells, MET activity is carefully regulated. However, in certain cancers, particularly NSCLC with MET exon 14 skipping mutations, the MET protein becomes overactive or abnormally expressed. This overactivity drives uncontrolled cell growth and survival, leading to tumor development and progression. Capmatinib works by binding to and blocking the activity of this mutated or overactive MET protein. By inhibiting MET, Capmatinib interferes with the signaling pathways that promote cancer cell proliferation and survival, ultimately leading to the reduction of tumor growth. This targeted approach is vital because it specifically addresses the underlying genetic driver of the cancer, making it an effective treatment option for patients whose tumors harbor this specific mutation.

Medical Uses

Capmatinib is approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a specific type of genetic alteration: MET exon 14 skipping mutations. This particular mutation leads to an overactive MET protein, which drives cancer cell growth. Before initiating treatment with Capmatinib, patients must undergo diagnostic testing to confirm the presence of this mutation. This ensures that the therapy is appropriately targeted to patients who are most likely to benefit. Capmatinib is often used in patients whose disease has progressed on or after prior systemic therapy, or in treatment-naïve patients who are not candidates for other first-line therapies. It offers a crucial treatment option for a subset of lung cancer patients who previously had limited therapeutic choices, improving outcomes and quality of life for those with this specific genetic profile.

Dosage

The recommended dosage of Capmatinib is typically 400 mg taken orally twice daily, with or without food. It is crucial to take the medication exactly as prescribed by your healthcare provider. Do not alter the dose or stop treatment without consulting your doctor. If a dose is missed, it should be skipped, and the next dose should be taken at the regularly scheduled time. Do not take two doses at once to make up for a missed dose. Dose adjustments may be necessary based on the patient's tolerance to the medication and the occurrence of certain side effects. Your doctor will monitor your condition and may reduce the dose or temporarily interrupt treatment if needed. It is important to swallow the tablets whole and not to crush, chew, or split them.

Side Effects

Like all medications, Capmatinib can cause side effects, although not everyone experiences them. Common side effects often include peripheral edema (swelling in the hands, ankles, or feet), nausea, fatigue, vomiting, dyspnea (shortness of breath), decreased appetite, muscle pain (myalgia), and cough. Most of these are mild to moderate and manageable. However, more serious side effects can occur and require immediate medical attention. These include interstitial lung disease (ILD) or pneumonitis, liver problems (hepatotoxicity), kidney impairment, pancreatitis, and vision problems. Patients should be vigilant for symptoms such as new or worsening cough, shortness of breath, fever, yellowing of the skin or eyes, dark urine, severe abdominal pain, or changes in vision. Regular monitoring of blood tests for liver and kidney function is typically performed during treatment with Capmatinib. Always report any unusual or severe symptoms to your healthcare provider promptly.

Drug Interactions

Capmatinib has the potential to interact with other medications, which can alter its effectiveness or increase the risk of adverse effects. It is primarily metabolized by the enzyme CYP3A, so co-administration with strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) can increase Capmatinib concentrations, potentially leading to increased toxicity. Conversely, strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John's wort) can decrease Capmatinib concentrations, potentially reducing its efficacy. Capmatinib can also affect the concentrations of other drugs, particularly those that are substrates of CYP1A2 or P-glycoprotein. Additionally, proton pump inhibitors (PPIs) and H2-receptor antagonists may reduce the absorption of Capmatinib, though this interaction is generally considered less significant. It is crucial to inform your doctor and pharmacist about all prescription and over-the-counter medications, herbal supplements, and vitamins you are currently taking to avoid potential drug interactions and ensure safe and effective treatment.

FAQ

What is a MET exon 14 skipping mutation?

A MET exon 14 skipping mutation is a specific genetic alteration in the MET gene found in some non-small cell lung cancers. This mutation leads to an abnormal MET protein that promotes uncontrolled cancer cell growth, making it a target for specific therapies like Capmatinib.

How is Capmatinib administered?

Capmatinib is administered orally as a tablet, typically taken twice a day, with or without food. It's important to swallow the tablets whole and not crush, chew, or split them.

Can Capmatinib cure lung cancer?

While Capmatinib can be highly effective in shrinking tumors and extending progression-free survival for patients with MET exon 14 skipping mutations, it is not generally considered a cure for metastatic lung cancer. It is a treatment aimed at controlling the disease and improving quality of life.

What should I do if I miss a dose of Capmatinib?

If you miss a dose, do not take an extra dose to make up for it. Simply take your next scheduled dose at the usual time. If you vomit after taking a dose, do not take an additional dose; continue with your next scheduled dose.

Is Capmatinib chemotherapy?

No, Capmatinib is not chemotherapy. It is a targeted therapy, which works by specifically inhibiting a protein (MET) that is overactive due to a specific genetic mutation in cancer cells, rather than broadly attacking rapidly dividing cells like traditional chemotherapy.

Products containing Capmatinib are available through trusted online pharmacies. You can browse Capmatinib-based medications at ShipperVIP or Medicenter.

Summary

Capmatinib (Tabrecta) stands as a vital targeted therapy for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. By specifically inhibiting the overactive MET receptor tyrosine kinase, it offers a precision medicine approach to combat cancer growth and progression. While generally effective, patients should be aware of potential side effects, including peripheral edema, nausea, and more serious adverse events like interstitial lung disease or liver problems. Close medical supervision, adherence to prescribed dosage, and open communication with healthcare providers about all medications are essential for safe and optimal treatment outcomes. Capmatinib represents a significant therapeutic option, improving the prognosis for a specific subset of lung cancer patients.